A detailed history of Acadian Asset Management LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Acadian Asset Management LLC holds 34,140 shares of BGNE stock, worth $6.11 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
34,140
Previous 947 3505.07%
Holding current value
$6.11 Million
Previous $135,000 5573.33%
% of portfolio
0.02%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$143.93 - $224.51 $4.78 Million - $7.45 Million
33,193 Added 3505.07%
34,140 $7.66 Million
Q2 2024

Aug 06, 2024

SELL
$129.52 - $174.32 $41,187 - $55,433
-318 Reduced 25.14%
947 $135,000
Q1 2024

May 10, 2024

BUY
$141.8 - $181.47 $120,388 - $154,068
849 Added 204.09%
1,265 $197,000
Q4 2023

Feb 13, 2024

BUY
$158.67 - $201.58 $66,006 - $83,857
416 New
416 $75,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.6B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.